STOCK RADAR
Filed
TRIBUNDER THE SECURITIES EXCHANGE ACT OF 1934 TRINITY BIOTECH PLCNasdaq

Novus Diagnostics reports 5.99% stake in Trinity Biotech ADS

SCHEDULE 13GInsider / OwnershipneutralImpact38

TRIB Price

Chart unavailable
N/A$0.00 (+0.00%)
Chart unavailable

A passive near-6% holder is notable given Trinity's small market cap but signals no immediate governance pressure

Novus Diagnostics Ltd. filed a Schedule 13G reporting ownership of 1,119,988 American Depositary Shares of Trinity Biotech, equal to 5.99% of ADS outstanding. Each ADS represents four Class A ordinary shares and the filer used 18,710,000 ADS outstanding to calculate percent. The filing certifies the stake is passive and not intended to influence control. No agreements, group members, or transactions were disclosed

  • Schedule 13G by Novus Diagnostics Ltd., filed 2026-03-06.
  • 1,119,988 ADS beneficially owned, representing 5.99% of ADS outstanding (based on 18,710,000 ADS).
  • Item 10 certification states holdings not for changing or influencing issuer control.
  1. Any amendment converting the filing to a Schedule 13D or adding active Item 4 intent.
  2. Material ownership increases above 2–5 percentage points or crossing 10%.
  3. Disclosed voting agreements, group formation, or related transaction filings.
AdvertisementResponsive display
AdvertisementResponsive display

TRIB Market Context

SectorHealthcare
IndustryMedical Devices & Diagnostics
Market Cap$7.06M
Shares Outstanding10.39M
Public Float10.02M
Public Float %96.4%
AdvertisementResponsive display
AdvertisementResponsive display

Original Filing Text

SEC filing text preserved from the raw item store.






Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Checkbox not checked   Rule 13d-1(b)
Checkbox checked   Rule 13d-1(c)
Checkbox not checked   Rule 13d-1(d)






SCHEDULE 13G




Comment for Type of Reporting Person:  (1) Based on 18,710,000 American Depository Shares outstanding as reported by the Issuer. Each American Depositary Share reported on this Schedule 13G represents four Class 'A' Ordinary Shares.


SCHEDULE 13G



 
Novus Diagnostics Ltd.
 
Signature:/s/ Keith O'Neill
Name/Title:Keith O'Neill/Chief Executive Officer
Date:03/06/2026

Comments accompanying signature:  The Reporting Persons disclaim beneficial ownership in the shares reported herein except to the extent of their pecuniary interest therein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and this report shall not otherwise be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 13(d) or Section 16 of the Exchange Act.